| Identification | More | [Name]
Azithromycin | [CAS]
83905-01-5 | [Synonyms]
11-(4-dimethylamino-3-hydroxy-6-methyl-oxan-2-yl)oxy-2-ethyl-3,4,10-tr
11-(4-DIMETHYLAMINO-3-HYDROXY-6-METHYL-TETRAHYDRO-PYRAN-2-YLOXY)-2-ETHYL-3,4,10-TRIHYDROXY-14-(5-HYDROXY-4-METHOXY-4,6-DIMETHYL-TETRAHYDRO-PYRAN-2-YLOXY)-3,5,6,8,10,12,13-HEPTAMETHYL-1-OXA-6-AZA-CYCLOPENTADECAN-15-ONE
9-DEOXO-9ALPHA-METHYL-9ALPHA-AZA-HOMOERYTHROMYCIN A
9-deoxo-9a-methyl-9a-aza-homoerythromycin a
AZITHROMYCIN
AZITHROMYCINE
N-METHYL-11-AZA-10-DEOXO-10-DIHYDROERYTHROMYCIN A
1-oxa-6-azacyclopentadecan-15-one,13-((2,6-dideoxy-3-c-methyl-3-o-methyl-alpha
3s*,4r*,5r*,8r*,10r*,11r*,12s*,13s*,14r*))-r-(2r
4,6-trideoxy-3-(dimethylamino)-beta-d-xylo-hexopyranosyl)oxy)-hyl-11-(((2
cp62993
-l-ribo-hexopyranosyl)oxy)-2-ethyl-3,4,10-trihydroxy-3,5,6,8,10,12,14-heptamet
xz405
AZYTHROMYCIN
Azithromycin CP2000 USP24
AZITHROMYCIN IMPURITY A6-DEMETHYLAZITHROMYCIN EP STANDARD
AZITHROMYCIN IMPURITY B3-DEOXYAZITHROMYCIN EP STANDARD
AZITHROMYCIN USP STANDARD
AZITHROMYCIN DIHYDRATE(COMPACTED)
Azithromycin(Dihydrate)Usp27 | [EINECS(EC#)]
617-500-5 | [Molecular Formula]
C38H72N2O12 | [MDL Number]
MFCD00873574 | [Molecular Weight]
748.98 | [MOL File]
83905-01-5.mol |
| Chemical Properties | Back Directory | [Appearance]
White Crystalline Powder | [Melting point ]
113-115°C | [alpha ]
D20 -37° (c = 1 in CHCl3) | [Boiling point ]
822.1±65.0 °C(Predicted) | [density ]
1.18±0.1 g/cm3(Predicted) | [storage temp. ]
Sealed in dry,2-8°C | [solubility ]
Practically insoluble in water, freely soluble in anhydrous ethanol and in methylene chloride. | [form ]
neat | [pka]
pKa 8.74 (H2O t=25 I=0.167) (Uncertain);9.45(H2O t=25 I=0.167) (Uncertain) | [color ]
White to Off-White | [Stability:]
Stable. Incompatible with strong oxidizing agents. | [optical activity]
[α]/D 45±2°, c = 1% in ethanol | [Usage]
Semi-synthetic macrolide antibiotic; related to Erythromycin A. Antibacterial | [BCS Class]
4 | [CAS DataBase Reference]
83905-01-5(CAS DataBase Reference) | [EPA Substance Registry System]
83905-01-5(EPA Substance) |
| Hazard Information | Back Directory | [Description]
Azithromycin (83905-01-5) is a long-acting macrolide antibiotic structurally related to erythromycin A
(EA), having a methyl-substituted nitrogen at position 9a in the aglycone ring.
Azithromycin is reported to be highly effective in the treatment of respiratory and urinary
infections; it has the advantages of being acid-stable and requiring a shorter course of
treatment than EA.
| [Chemical Properties]
White Crystalline Powder | [Originator]
Pliva (Yugoslavia) | [Definition]
ChEBI: A macrolide antibiotic useful for the treatment of bacterial infections. | [Indications]
Azithromycin(83905-01-5) in a 500-mg dose three times a week has been shown to yield a
60% reduction in inflammatory papules in 83% of patients enrolled in a 12-
week study. There is no associated pseudotumor cerebri and, therefore,
it can be used for an acne flare during early Accutane therapy.
| [Manufacturing Process]
To a solution of 0.54 g (0.000722 mole) of 11 aza-10-deoxo-10-
dihydroerythromycin A in 20 ml CHCl3 were added 0.0589 ml (0.000741 mole)
of formaldehyde (approx. 35% w./w.) and 0.00283 g (0.000735 mole) of
formic acid (approx. 98 to 100% w./w.). The reaction mixture was stirred for
8 hours while heating under reflux, then cooled to ambient temperature,
whereupon were added 15 ml of water (pH 5.8). The pH of the reaction
mixture was adjusted to 5.0 by means of 2 N HCl, whereupon the CHCl3 layer
was separated. To the aqueous part was added 15 ml of CHCl3, the pH of the
reaction suspension was adjusted to 7.5 by means of 20% NaOH, the layers
were separated and subsequently the aqueous layer was extracted three times
with 15 ml of CHCl3. The combined chloroform extracts having pH 7.5 were
dried over K2CO3 and evaporated under reduced pressure, yielding 0.45 g
(82.4%) of N-methyl-11-aza-10-deoxo-10-dihydro erythromycin A
(azithromycin), m.p. 113°-115°C. [α]D
20= - 37.0 (1% in CHCl3). | [Brand name]
Zithromax (Pfizer);
Zmax (Pfizer);Sunamed. | [Therapeutic Function]
Antibiotic | [Antimicrobial activity]
It is less potent than erythromycin A against Gram-positive isolates, but is more active against Gram-negative bacteria. It is four times more potent than erythromycin A against H. influenzae, N. gonorrhoeae and Campylobacter spp., and twice as active against Mor. catarrhalis. It also exhibits superior potency against Enterobacteriaceae, notably Esch. coli, Salmonella enterica serotypes, and Shigella spp. It is active against Mycobacteria, notably the M. avium complex and against intracellular micro-organisms such as Legionella and Chlamydia spp.
Chemical modification at the 9 position of the erythronolide A ring of erythromycin A blocks the internal ketalization and markedly improves acid stability. At pH 2, loss of 10% activity occurred in less than 4 s with erythromycin A, but took 20 min with azithromycin. The AUC at 0–24 h is 4.5 mg.h/L. The level is only slightly increased on repeated dosing.
Binding to plasma protein varies with the concentration, from around 50% at 0.05 mg/L to 7.1% at 1 mg/L. The apparent elimination half-life is dependent upon sampling interval: between 8 and 24 h it ranged from 11 to 14 h; between 24 and 72 h it was 35–40 h.
It rapidly penetrates the tissues, reaching levels that approach or, in some cases, exceed the simultaneous plasma levels and persist for 2–3 days. Only about 6% of the dose is found in urine in the first 24 h.
| [General Description]
The spectrum of antimicrobial activity of azithromycin issimilar to that observed for erythromycin and clarithromycinbut with some interesting differences. In general,it is more active against Gram-negative bacteria and less activeagainst Gram-positive bacteria than its close relatives.The greater activity of azithromycin against H. influenzae,M. catarrhalis, and M. pneumoniae coupled with its extendedhalf-life permits a 5-day dosing schedule for thetreatment of respiratory tract infections caused by thesepathogens. The clinical efficacy of azithromycin in the treatmentof urogenital and other sexually transmitted infectionscaused by Chlamydia trachomatis, N. gonorrhoeae, H.ducreyi, and Ureaplasma urealyticum suggests that singledosetherapy with it for uncomplicated urethritis or cervicitismay have advantages over use of other antibiotics. | [Pharmaceutical Applications]
A semisynthetic derivative of erythromycin A, supplied as the dihydrate for oral administration. | [Biological Activity]
Macrolide antibiotic. Inhibits 50S ribosomal subunit formation and elongation at transpeptidation step in gram-positive and gram-negative organisms. Orally active with improved pharmacokinetics over erythromycin in mouse models. | [Clinical Use]
Azithromycin(83905-01-5) is commonly the first choice for treatment of infections that require a macrolide.
| [Veterinary Drugs and Treatments]
Azithromycin(83905-01-5) with its relative broad spectrum and favorable pharmacokinetic
profile may be useful for a variety of infections in
veterinary species. Little data is published at this time, however.
Azithromycin has been shown to be ineffective in the treatment of
Mycoplasma haemofelis in cats.
Azithromycin may be potentially useful for treating Rhodococcus
infections in foals.
| [Drug interactions]
Potentially hazardous interactions with other drugs
Anti-arrhythmics: increased toxicity with
disopyramide; increased risk of ventricular
arrhythmias with dronedarone - avoid.
Antibacterials: possibly increased rifabutin
concentration (increased risk of uveitis and
neutropenia) - reduce dose of rifabutin.
Anticoagulants: effect of coumarins may be enhanced.
Antidepressants: the manufacturer of reboxetine
advises to avoid concomitant use.
Antihistamines: may inhibit the metabolism of
mizolastine (risk of hazardous arrhythmias) - avoid.
Antimalarials: avoid with artemether/lumefantrine;
increased risk of ventricular arrhythmias with
piperaquine with artenimol - avoid.
Antipsychotics: increased risk of ventricular
arrhythmias with droperidol - avoid.
Antivirals: concentration possibly increased by ritonavir.
Ciclosporin: may inhibit the metabolism of
ciclosporin (increased ciclosporin levels).
Colchicine: treatment with both agents has been
shown in a study to increase the risk of fatal
colchicine toxicity, especially in patients with renal
impairment - avoid.
Ergot alkaloids: increased risk of ergotism - avoid.
Statins: possible increased risk of myopathy with
atorvastatin and simvastatin. | [Metabolism]
In pharmacokinetic studies it has been demonstrated that
the concentrations of azithromycin measured in tissues
are noticeably higher (as much as 50 times) than those
measured in plasma, which indicates that the agent strongly
binds to tissues. Azithromycin is excreted in bile mainly as
unchanged drug. Ten metabolites have also been detected in
bile, which are formed through N- and O- demethylation
in the liver, hydroxylation of desosamine - and aglycone
rings and cleavage of cladinose conjugate. The metabolites
of azithromycin are not microbiologically active | [storage]
Store at -20°C | [Mode of action]
Azithromycin(83905-01-5) reversibly binds to the 50S ribosomal subunit of the 70S ribosome of sensitive microorganisms, thereby inhibiting the translocation step of protein synthesis, wherein a newly synthesized peptidyl tRNA molecule moves from the acceptor site on the ribosome to the peptidyl (donor) site, and consequently inhibiting RNA-dependent protein synthesis leading to cell growth inhibition and cell death.
|
| Questions And Answer | Back Directory | [The most commonly used antibiotics]
Because the side effects of Azithromycin(83905-01-5) are less than Cephalosporins, now Azithromycin is the most commonly used antibiotics for bacterial infection-related diseases in our hospital clinic. This drug is a second generation semi-synthetic derivative of macrolide, whose structure is different from Erythromycin. It inserted a methyl-substituted nitrogen in 9a site of Erythromycin lactone ring, generating a 15-membered ring macrolide.
The mechanism of action of Azithromycin is similar to Erythromycin. By binding to 50S subunit susceptible ribosome, Azithromycin inhibits protein synthesis which depends on RNA to show an antibacterial effect, retaining the antibacterial spectrum of typical Erythromycin. As for activity to chlamydia, Azithromycin is similar to Erythromycin. Compared with Erythromycin, antibacterial activity for gram-negative bacteria has been significantly improved, antibacterial activity for Haemophilus influenzae and Neisseria gonorrhoeae is more four times than Erythromycin, antimicrobial activity for Legionella bacteria is more about 2 times than Erythromycin, and antibacterial activity for Enterobacteriaceae is significantly stronger than Erythromycin. The MIC of most gram-negative bacteria is less than 1μg/ml. Staphylococcus aureus and Streptococcus pyogenes show cross-resistance on Azithromycin and Erythromycin. For toxoplasmosis and syphilis, Azithromycin also has a good role in the killing.
| [Pharmacokinetics]
It is rapidly absorbed after oral administration, and its bioavailability is 37%. After a single oral dose of 0.5g, the peak time is 2.5 to 2.6 hours, peak plasma concentration (Cmax) is 0.4~0.45mg/L. This product is widely distributed in the body, and concentrations in each tissue are up to 10 to 100 times of the blood concentration over the same period. The plasma concentrations are high in macrophages and fibroblasts , the former can transport Azithromycin to inflammation sites. After a single dose administration of the product, elimination half-life of plasma concentration is 35 to 48 hours, more than 50% of the administered dose is excreted in the bile duct in original shape, and after 72 hours administration about 4.5% is excreted in the urine in original shape. With increasing plasma concentrations, serum protein binding rate of this product decreased. When the plasma concentration is 0.02 μg/mL, serum protein binding rate is 15%; when the blood concentration is 2 μg/mL, serum protein binding rate is 7%. | [Antibacterial spectrum]
1. Gram-positive aerobic bacteria, such as Staphylococcus aureus, Streptococcus pyogenes (A group β-hemolytic streptococcus), Streptococcus pneumoniae, α-hemolytic Streptococci (Streptococcus viridans group) and the other Streptococcus, Diphtheria (rodlike) bacteria.
2. Gram-negative aerobic bacteria, such as Haemophilus influenzae, Haemophilus parainfluenza, catarrhal bacteria, Acinetobacter, Yersinia, Legionella spp, Bordetella pertussis, parapertussis, Shigella, Pasteurella spp., Vibrio cholerae, Vibrio parahaemolyticus, Shiga topiramate o Aeromonas. The activities for Escherichia coli, Salmonella enteritidis, Salmonella typhi, Enterobacter, addicted to waterborne Aeromonas and Klebsiella are not the same, and sensitivity test is needed.
3. Anaerobic bacteria, such as Bacteroides spp., Clostridium perfringens, Lactococcus digestion, digestion Streptococcus, Fusobacterium, Propionibacterium acnes.
4. Sexually transmitted disease microorganisms, such as Chlamydia trachomatis, Treponema pallidum, Neisseria gonorrhoeae, Haemophilus Duke.
5. Other microorganisms, such as Borrelia burgdorferi (Lyme pathogens), Chlamydia pneumoniae, Mycoplasma hominis, Ureaplasma urea, bending genus, mononucleosis and Lee de bacilli.
Azithromycin shows cross-resistance for Gram-positive bacteria with Erythromycin-resistant and various strains of Staphylococcus aureus with methicillin-resistant, and Gram-positive bacteria such as Proteus, Serratia, Morgan bacteria, Pseudomonas aeruginosa are usually resistant to Azithromycin.
| [Usage and dosage]
Adult
General dose
Oral administration
1. Community-acquired pneumonia: intravenous infusion for at least 2 days turning into oral administration, once 500 mg, 1 times a day, 7-10 day for a course.
2. For sexually transmitted diseases caused by Chlamydia trachomatis, Duke Haemophilus or sensitive Neisseria gonorrhoeae, only a single oral dose of 1g.
3. Pelvic inflammation disease: intravenous infusion for 1-2 days turning into oral administration, once 250 mg, 1 time a day, 7 day a course of treatment.
Intravenous infusion
1.Community-acquired pneumonia: one 500mg, once a day, at least continuous medication for 2 days, followed by turning into oral administration. Usage and dosage see oral administration items.
2. Pelvic inflammatory disease: an adult once 500 mg, 1 times a day, 1-2 days of medication, using the drug for oral administration. Usage and dosage see oral administration items.
Renal insufficiency dose
Patients with mild renal insufficiency (creatinine clearance rate is greater than 40ml/min) are no need for dose adjustment.
Hepatic insufficiency dose
Patients with mild to moderate hepatic dysfunction are no need for dose adjustment.
Elderly dosage: Usage and dosage is same as adults.
Children
General dose
Oral administration
1. General infections: total dose for children is 30 mg/kg, once 10 mg/kg, 1 times a day, consecutive administration for 3 days; or the first day 10 mg/kg, 2-5 days, once 5 mg/kg, 1 times a day, continuous administration for 5 days.
2. Otitis media and pneumonia: Day 1 10 mg/kg administered at draught, a day of maximum amount does not exceed 500 mg; 2-5 day, a day 5 mg/kg administered at draught,a day of maximum amount does not exceed 250 mg.
3. Pharyngitis and tonsillitis: a day 12 mg/kg administered at draught, continuous administration for 5 days. A day of maximum amount does not exceed 500 mg. Administration can also refer to the following table.
Children pharyngitis and tonsillitis (both 1 time a day)
Weight Age three days administration plan five days administration plan
15kg or less 1-3years old once 100 mg, continuous administration for 3 days
15-25kg 3-8 years old once 200 mg, continuous administration for 3 days. first day once 200mg，2-5 days, once 100 mg
26-35kg 9-12 years old once 300 mg, continuous administration for 3 days. first day once 300mg，2-5 days, once 150 mg
36-45kg 13-15 years old once 400 mg, continuous administration for 3 days. first day once 400mg，2-5 days, once 200 mg
45kg or more Usage and dosage is same as adults. | [Side effects]
Patients are well tolerated to Azithromycin, incidence of adverse reactions is low.
1. Gastrointestinal: after treatment, fear of food, abdominal pain, diarrhea, nausea, vomiting, abdominal distension (<1%), gastritis (<1%), mucositis (<1%), pseudomembranous colitis, etc. can occur, butthe incidence was significantly lower than Erythromycin; small number of patients using the drug even can cause stomatitis, oral candidiasis (<1%); rare tongue discoloration.
2. Liver: alanine aminotransferase (ALT), aspartate aminotransferase (AST), lactate dehydrogenase, bilirubin, alkaline phosphatase may increase transiently. The drug has been reported to cause hepatitis and cholestatic jaundice; occasionally cause liver necrosis and liver failure, but the relationship of rare death with the drug has not been determined.
3. Neuropsychiatric system: headache (<1%), drowsiness (<1%). In addition, the relationship of dizziness, convulsions, paresthesia, increased activity, aggressive reactions, nervousness, anxiety, anxiety with the drug has not been determined.
4. Allergies: fever, rash, itching may occur. Side effects which are associated with the drug have not been determined, including urticaria, bronchospasm (<1%), photosensitivity, joint pain. Anaphylactic shock and angioedema are extremely rare. Severe cases may occur erythema multiforme, Stevens-Johnson syndrome and toxic epidermal dissolve and necrosis. Drug should be discontinued immediately, and take appropriate measures.
5. Blood: may have the reduction of white blood cells, neutropenia, thrombocytopenia.
6. Urogenital system: common vaginitis; it may have a transient increase in serum creatinine; the relationship of existence of interstitial nephritis and acute renal failure with the drug has not been determined.
7. Ear: patients taking Azithromycin had been hearing impairment, including hearing loss, tinnitus and (or) epicophosis, which is related to high-dose use of the drug and mostly reversible.
8. Local: when the injection, injection site pain and local inflammation may occur.
9. Cardiovascular system: the relationship of cardiac arrhythmia, ventricular tachycardia with the drug has not been determined.
10. Other: it is reported rarely that drug causes changes in taste (<1%). | [Precautions]
1. Patients who are allergic to this product, Erythromycin or any other macrolide drug are contraindicated.
2. Application for pregnant women should be fully weighed; application for lactating women requires careful consideration; efficacy and safety for treatment of age <6 months of pediatric otitis media, community-acquired pneumonia and age <2 years pharyngitis or tonsillitis in children have not been determined.
3. Patients with mild renal insufficiency (creatinine clearance rate> 40ml/min) are no need for dose adjustments, but for more serious patients with renal insufficiency, should be used with caution.
4. Since the hepatobiliary system is the main route of excretion of the product, patients with liver dysfunction should be used with caution. Severe liver disease should not be used. Regular follow-up liver function during treatment.
5. Food can affect the absorption of Azithromycin, so oral administration is needed at 1h before meals or after meals 2h.
6. During the treatment if allergy occurs (such as angioneurotic edema, skin reactions, Stevens-Johnson syndrome and toxic epidermal necrolysis, etc.), patients should be discontinued immediately, and take appropriate measures. If patients appear diarrhea symptom, pseudomembranous colitis should be considered, if the diagnosis is determined, appropriate therapeutic measures should be took, including maintenance of water and electrolyte balance, proteins supplement, etc.
7. If suspected the combined anaerobic infectionsmerger anaerobic infections, Azithromycin should be combined with anti-anaerobic drugs during treatment of pelvic inflammatory disease. | [Clinical evaluation]
Foreign reports compared the Azithromycin(83905-01-5) with Cefaclor in treatment of acute lower respiratory tract infection. Azithromycin group had 191 cases, once daily for 5 consecutive days, the first time 0.5g, after each 0.25 g; Cefaclor group had 81 cases, once 0.5 g, 3 times a day for 10 consecutive days. Clinical cure and improvement rates in both groups were 96% and 94%, respectively, while the bacteriological clearance rate was 88%.
In Huashan Hospital, Shanghai Medical University, 110 patients with respiratory tract infections were oral administration of the product, the total effective rate was 93.6%, bacterial clearance rate was 91.4%, the incidence of adverse reactions was 5.4%.
The product has an excellent effect on the genitourinary system infections caused by Neisseria gonorrhoeae, Chlamydia trachomatis, Mycoplasma. Shanghai Dermatology Prevention Centre used this product to treat patients with non-gonococcal urethritis and gonorrhea, including 30 cases of chlamydia infection, 19 cases of mycoplasma infection, 28 cases of Neisseria gonorrhoeae infection, and oral administration, a single dose 1 g. The cure rates were 100%, 85%, 96.5%, respectively, and total effective rate was 100%.
Previous studies suggested that as for people with high risk of cardiovascular, Azithromycin can increase the risk of cardiovascular mortality. But research in the real world population is lacked. Therefore, there is a large-scale population study in the real world. This is a 18-64-year-old national historical cohort study in Denmark, which is related to information including the prescription registration database, causes of death in patients, and general condition of the patient in 1997 to 2010, etc. The use of Azithromycin up to 110 million treatment courses and not use of antibiotics population controls (1: 1) were evaluated. In addition, compared with 7.36 million passengers using penicillin V (also based on propensity score matching), causes of death from cardiovascular were observed.
The results showed that the use of Azithromycin and not use any antibiotics population significantly increased the risk of cardiovascular death (RR: 2.85, 95CI: 1.13-7.24). In the Azithromycin group, 17 patients died. In the penicillin V group, 146 patients died (RR: 0.93,95% CI: 0.56-1.55). Azithromycin does not increase the risk of cardiovascular death in young and elderly patients.
| [Uses]
Azithromycin(83905-01-5) is used to treat certain bacterial infections, such as bronchitis; pneumonia; sexually transmitted diseases (STD); and infections of the ears, lungs, sinuses, skin, throat, and reproductive organs.As for Gram-negative bacteria such as Haemophilus influenzae, Salmonella, E. coli, Shigella bacteria, it have strong antibacterial activity. And it is acid stable and well tolerated. It has a very good therapeutic effect on respiratory tract infections, skin and soft tissue infections, sexually transmitted diseases which are caused by sensitive bacteria.
| [Production methods]
Azithromycin(83905-01-5) is prepared by using erythromycin A as raw material, after oximation, Beckmann rearrangement under the action of hydrochloric acid, and then dehydration, reduction and methylation.
|
|
|